Whole Food Women's Multi 40+
Texto original en francés.
Producto de salud natural autorizado en Canadá
Si este producto se vendiera en Francia
- Dose déclarée au-delà d'une limite
Vitamine B6: hasta 5 mg al día según la posología publicada por Health Canada (1 unités posologiques par jour au plus, pour les adultes), por encima de la dosis máxima de 2 mg fijada en Francia para un complemento alimenticio (orden de 2006, sin revisar desde noviembre de 2006).
arrêté du 9 mai 2006, annexe III. Órdenes francesas de 9 de mayo de 2006 y 14 de noviembre de 2006 tal como se publicaron en el Diario Oficial (dosis diarias máximas), consultado el 21 de octubre de 2026.
- Conditions légales
Lepidium meyenii Walp.: L'absence d'alcaloïdes doit être démontrée par des rapports d'analyse.
arrêté du 24 juin 2014, annexe I. Órdenes francesas de 9 de mayo de 2006 (nutrientes), 24 de junio de 2014 (plantas) y 26 de septiembre de 2016 (otras sustancias), fondo LEGI consolidado, consultado el 23 de octubre de 2026.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. Órdenes francesas de 9 de mayo de 2006 (nutrientes), 24 de junio de 2014 (plantas) y 26 de septiembre de 2016 (otras sustancias), fondo LEGI consolidado, consultado el 23 de octubre de 2026.
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. Órdenes francesas de 9 de mayo de 2006 (nutrientes), 24 de junio de 2014 (plantas) y 26 de septiembre de 2016 (otras sustancias), fondo LEGI consolidado, consultado el 23 de octubre de 2026.
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
arrêté du 24 juin 2014, annexe I. Órdenes francesas de 9 de mayo de 2006 (nutrientes), 24 de junio de 2014 (plantas) y 26 de septiembre de 2016 (otras sustancias), fondo LEGI consolidado, consultado el 23 de octubre de 2026.
Solo se calcula una cantidad diaria para una posología oral explícita para adultos, expresada por día y en una unidad sólida correspondiente a la forma del producto. No se extrapolan las unidades ambiguas, los líquidos, los polvos ni las dosis pediátricas. Una cantidad no calculada no se compara con los límites de dosis. Este análisis no constituye una autorización de venta en Francia ni una evaluación de seguridad o eficacia.
Composición
| Ingrediente medicinal y fuente | Por unidad posológica, según la fuente | Máximo diario, adulto |
|---|---|---|
| Lepidium meyenii Fuente : Racine | 7,5 milligramme | No calculada |
| Taraxacum officinale Fuente : Racine | 6 milligramme | No calculada |
| Vitamine C Fuente : Acide ascorbique | 60 milligramme | 60.000 µg |
| Vitamine E Fuente : Acétate de d-alpha-tocophéryle Potencia : 30 UI | 20 mg AT | No calculada |
| Thiamine Fuente : Chlorhydrate de thiamine | 2 milligramme | 2.000 µg |
| Riboflavine Fuente : Riboflavine | 2 milligramme | 2.000 µg |
| Niacinamide Fuente : Niacinamide | 20 milligramme | No calculada |
| Vitamine B6 Fuente : Chlorhydrate de pyridoxine | 5 milligramme | 5.000 µg |
| Biotine Fuente : Biotine | 150 microgrammes | No calculada |
| Acide pantothénique Fuente : D-Pantothénate de calcium | 10 milligramme | 10.000 µg |
| Folate Fuente : Folate | 200 microgrammes | No calculada |
| Vitamine B12 Fuente : Cyanocobalamine | 25 microgrammes | No calculada |
| Calcium Fuente : Carbonate de calcium | 25 milligramme | 25.000 µg |
| Calcium Fuente : Lithothamnion corallioides - En entier | 25 milligramme | 25.000 µg |
| Chrome Fuente : Chlorure de chrome (III) | 60 microgrammes | No calculada |
| Cuivre Fuente : Sulfate de cuivre (II) | 750 microgrammes | No calculada |
| Iode Fuente : Iodure de potassium | 75 microgrammes | No calculada |
| Magnésium Fuente : Oxyde de magnésium | 6 milligramme | 6.000 µg |
| Magnésium Fuente : Lithothamnion corallioides - En entier | 6 milligramme | 6.000 µg |
| Magnésium Fuente : Carbonate de magnésium | 6 milligramme | 6.000 µg |
| Manganèse Fuente : Chlorure de manganèse (II) | 1 milligramme | 1.000 µg |
| Molybdène Fuente : Molybdate de sodium (VI) | 10 microgrammes | No calculada |
| Sélénium Fuente : Sélénate de sodium | 75 microgrammes | No calculada |
| Zinc Fuente : Oxyde de zinc | 7,5 milligramme | 7.500 µg |
| Equisetum arvense Fuente : Sommité Relación de extracción : 6:1 Equivalente de planta seca : 180 milligramme | 30 milligramme | No calculada |
| Vitex agnus-castus Fuente : Fruit | 15 milligramme | No calculada |
| Ginkgo biloba Fuente : Feuille Relación de extracción : 50:1 Equivalente de planta seca : 375 milligramme Potencia : 24 % Flavonoid glycosides | 7,5 milligramme | No calculada |
| Ginkgo biloba Fuente : Feuille Potencia : 6 % Terpene lactones | No especificada | No calculada |
| Hericium erinaceus Fuente : Mycelia | 5 milligramme | No calculada |
| Brassica oleracea var. italica Fuente : Sommité | 12,5 milligramme | No calculada |
| Vaccinium macrocarpon Fuente : Fruit | 12,5 milligramme | No calculada |
| Brassica oleracea var. viridis Fuente : Feuille | 12,5 milligramme | No calculada |
| Phyllanthus emblica Fuente : Fruit Relación de extracción : 50:1 Equivalente de planta seca : 375 milligramme | 7,5 milligramme | No calculada |
| Petroselinum crispum Fuente : Sommité | 6 milligramme | No calculada |
| Arthrospira platensis Fuente : Arthrospira platensis - en entier | 7,5 milligramme | No calculada |
| Withania somnifera Fuente : Racine | 7,5 milligramme | No calculada |
| Ophiocordyceps sinensis Fuente : Stroma | 5 milligramme | No calculada |
| Inonotus obliquus Fuente : Mycelia | 5 milligramme | No calculada |
| Grifola frondosa Fuente : Mycelia | 5 milligramme | No calculada |
| Lentinula edodes Fuente : Mycelia | 5 milligramme | No calculada |
| Ganoderma lucidum Fuente : Mycelia | 5 milligramme | No calculada |
| Echinacée purpurea Fuente : Sommité Relación de extracción : 6:1 Equivalente de planta seca : 30 milligramme | 5 milligramme | No calculada |
| Vitamin K1 Fuente : Vitamine K1 | 80 microgrammes | No calculada |
| bêta-carotène Fuente : bêta-carotène Potencia : 5.000 UI | 3.000 microgrammes | No calculada |
| Vitamine D Fuente : Cholécalciférol Potencia : 1.000 UI | 25 microgrammes | No calculada |
Ingredientes no medicinales
Acide stéarique, Tapioca, Maltodextrine
Dosis recomendadas en Canadá
| Población | Edad | Cantidad por toma | Frecuencia |
|---|---|---|---|
| Adultes | Non précisée | 1 Comprimé | 1 Tous les jours |
Usos autorizados en Canadá
NHelps to form red blood cells. Helps the body to metabolize carbohydrates, fats and proteins. Helps normal growth and development. Helps in tissue formation. Helps in the development of bones, cartilage, teeth and gums. Helps in connective tissue formation. Helps in wound healing. An antioxidant for the maintenance of good health. Helps in the absorption and use of calcium and phosphorus. Calcium intake, when combined with sufficient vitamin D, a healthy diet, and exercise may reduce the risk of developing osteoporosis. Provides support for healthy glucose metabolism. Helps in the function of the thyroid gland. Source of vitamin A for the maintenance of good health. Source of vitamin A to help maintain eyesight, skin membranes and immune function. Source of vitamin A to help in the development and maintenance of night vision.
Texto original en inglés.
Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.
Advertencias en Canadá
Cautions and Warnings : Consult a health care practitioner prior to use if you are taking hormone-containing medications such as progesterone preparation, oral contraceptives or hormone replacement therapy. Consult a health care practitioner prior to use if you are taking medications for diabetes, high blood pressure, or seizures. If you are taking immunosuppressants, consult a health care practitioner prior to use. If you have an autoimmune disorder, consult a health care practitioner prior to use. If you have a progressive systemic disease such as tuberculosis, collagenosis, multiple sclerosis, AIDS and/or HIV infection, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you have a history of kidney stones. If you have or develop abdominal pain, nausea, fever or vomiting, consult a health care practitioner. If you have liver or gall bladder diseases, and/or intestinal obstruction, consult a health care practitioner prior to use. Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a physician. Consult a health care practitioner prior to use if you are taking health products which may aggravate electrolyte imbalance or are dehydrated. Do not use if you are taking health products that affect blood coagulation (e.g. blood thinners, clotting factor replacements, acetylsalicylic acid, ibuprofen, fish oils, vitamin E) as this may increase the risk of spontaneous bleeding. Do not use if you have oedema due to a kidney or cardiovascular disease. Hypersensitivity/allergy can occur; in which case, discontinue use. Rare cases of severe allergic reactions have been known to occur. Use caution if you are allergic to plants of the Daisy family. Laxative effect may occur, in which case, discontinue use. Consumption with alcohol, other drugs or natural health products with sedative properties is not recommended.
Texto original en inglés.
Ficha del producto
- Titular
- WN Pharmaceuticals Ltd
- NPN o DIN-HM
- 80068509
- Estado
- Licencia activa
- Fecha de licencia
- 13 de abril de 2016
- Fecha de revisión
- 24 de mayo de 2024
- Forma
- Comprimé
- Vía de administración
- Orale
- Tipo de solicitud
- Non traditionnelle
Fuente
Ficha oficial de Health Canada, licencia 80068509
Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Texto original en inglés.
Texto original en francés.
La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.
Advertencias oficiales (Health Canada)
Health Canada publica advertencias sobre estos ingredientes:
- Lepidium meyenii
Leer la advertencia, cuándo se aplica y los estudios citados
Texto original oficial en inglés.
Maca - Lepidium Meyenii
Vía de administración: Oral
Precauciones y advertencias
Condición de aplicación: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Se aplica a los productos: providing 0.6 g or more dried root/hypocotyl, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a blood pressure condition (Valentova et al. 2008).
Fuentes citadas por Health Canada (1)
- Valentova K, Stejskal D, Bartek J, Dvoráckova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food and Chemical Toxicology 2008;46(3):1006-1013. PubMed Ensayo aleatorizado
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).
Fuentes citadas por Health Canada (2)
- Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Ensayo aleatorizado
- Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed
Condición de aplicación: Healthy mood balance; Sexual health.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression (Brotto 2010; Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).
Fuentes citadas por Health Canada (3)
- Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior 2010;39(2):221-239. PubMed Artículo de revisión
- Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Ensayo aleatorizado
- Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed
- Vitex agnus-castus
Leer la advertencia, cuándo se aplica y los estudios citados
Texto original oficial en inglés.
CHASTE TREE - VITEX AGNUS-CASTUS
Vía de administración: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Precauciones y advertencias
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
Fuentes citadas por Health Canada (4)
- Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
Contraindicaciones
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
Fuentes citadas por Health Canada (9)
- Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
- Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
- Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
- Ginkgo biloba
Leer la advertencia, cuándo se aplica y los estudios citados
Texto original oficial en inglés.
GINKGO - GINKGO BILOBA
Vía de administración: Oral
Precauciones y advertencias
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).
Fuentes citadas por Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
- WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).
Fuentes citadas por Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindicaciones
Do not use if you are having a surgery (Gardner and McGuffin 2013).
Fuentes citadas por Health Canada (1)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).
Fuentes citadas por Health Canada (3)
- Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Revisión sistemática
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
- Vaccinium macrocarpon
Leer la advertencia, cuándo se aplica y los estudios citados
Texto original oficial en inglés.
CRANBERRY - VACCINIUM MACROCARPON
Vía de administración: Oral
Precauciones y advertencias
Condición de aplicación: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Fuentes citadas por Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Ensayo aleatorizado
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Fuentes citadas por Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Caso clínico
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condición de aplicación: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografía de Health Canada del 27 de marzo de 2026
DRIED CRANBERRY JUICE
Vía de administración: Oral
Precauciones y advertencias
Condición de aplicación: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Fuentes citadas por Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Ensayo aleatorizado
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Fuentes citadas por Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Caso clínico
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condición de aplicación: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Phyllanthus emblica
Leer la advertencia, cuándo se aplica y los estudios citados
Texto original oficial en inglés.
Amla - Phyllanthus Emblica
Vía de administración: Oral
Precauciones y advertencias
Condición de aplicación: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).
Fuentes citadas por Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Se aplica a los productos: providing more than 3 grams of amla, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).
Fuentes citadas por Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Condición de aplicación: Amlapitta, Digestive tonic.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condición de aplicación: Laxative.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).
Fuentes citadas por Health Canada (3)
- CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
- Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.
Contraindicaciones
Condición de aplicación: Laxative.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).
Fuentes citadas por Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Reacciones adversas conocidas
Condición de aplicación: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.
When using this product you may experience a laxative effect.
- Withania somnifera
Leer la advertencia, cuándo se aplica y los estudios citados
Texto original oficial en inglés.
ASHWAGANDHA - WITHANIA SOMNIFERA
Vía de administración: Oral
Precauciones y advertencias
Condición de aplicación: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condición de aplicación: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Fuentes citadas por Health Canada (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Fuentes citadas por Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
- Vitamine D
Leer la advertencia, cuándo se aplica y los estudios citados
Texto original oficial en inglés.
VITAMIN D (>1,000 - 2,500 IU)
Vía de administración: Oral
Precauciones y advertencias
Condición de aplicación: All products except products containing zinc sourced from picolinate requiring a contraindication.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condición de aplicación: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).
Fuentes citadas por Health Canada (2)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).
Fuentes citadas por Health Canada (3)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
- DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.
Se aplica a los productos: containing vitamin K2.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).
Fuentes citadas por Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
Se aplica a los productos: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).
Fuentes citadas por Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
Contraindicaciones
Condición de aplicación: All products.
Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).
Fuentes citadas por Health Canada (2)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
Se aplica a los productos: containing zinc sourced from picolinate.
Do not use if you are pregnant or breastfeeding (NNHPD 2026).
Fuentes citadas por Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
Reacciones adversas conocidas
Condición de aplicación: All products.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).
Fuentes citadas por Health Canada (2)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
Se aplica a los productos: providing more than 350 mg of magnesium per day.
When using this product you may experience diarrhea (NNHPD 2026).
Fuentes citadas por Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.
Lista en la revisión oficial del (registro: Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias).
¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.